{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:31:52Z","timestamp":1789014712202,"version":"build-2803163510"},"reference-count":18,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T00:00:00Z","timestamp":1545350400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2019,2]]},"abstract":"Summary<\/jats:title>Bendamustine (B) with rituximab (R) is a standard frontline treatment for medically fit follicular lymphoma (FL<\/jats:styled-content>) patients. The safety and efficacy of maintenance rituximab (MR<\/jats:styled-content>) after BR<\/jats:styled-content> induction has not been formally compared to observation for FL<\/jats:styled-content>, resulting in disparate practice patterns. Prospective trials have shown benefit of MR<\/jats:styled-content> after R\u2010CHOP<\/jats:styled-content> (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or R\u2010CVP<\/jats:styled-content> (rituximab, cyclophosphamide, vincristine, prednisone), yet recent data from the GALLIUM<\/jats:styled-content> study comparing outcomes of patients treated with chemotherapy with R or obinutuzumab (G) showed higher than anticipated fatal adverse events with BR<\/jats:styled-content>\/BG<\/jats:styled-content>. In order to assess the efficacy and tolerability of MR<\/jats:styled-content> after BR<\/jats:styled-content>, we retrospectively collected data on 640 newly diagnosed patients treated with FL<\/jats:styled-content>. We found that patients who achieved partial remission (PR<\/jats:styled-content>) after \u22654 cycles of BR<\/jats:styled-content> had improved duration of response (DOR<\/jats:styled-content>) with MR<\/jats:styled-content> vs. no maintenance, whereas those in complete remission did not. These findings were confirmed in a validation cohort. In the entire study population, the known fatal adverse event rate after BR<\/jats:styled-content> was 2\u00b75% and did not significantly differ in those receiving MR <\/jats:styled-content>versus<\/jats:italic> no maintenance. [Correction added on 14 January 2019, after online publication: The preceding sentence has been corrected in this current version.] Within the limitations inherent to retrospective analysis, these data suggest that FL<\/jats:styled-content> patients with a PR<\/jats:styled-content> to BR<\/jats:styled-content> experience prolongation of remission with MR<\/jats:styled-content> with an acceptable safety profile.<\/jats:p>","DOI":"10.1111\/bjh.15720","type":"journal-article","created":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T15:09:48Z","timestamp":1545404988000},"page":"524-535","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Maintenance rituximab or observation after frontline treatment with bendamustine\u2010rituximab for follicular lymphoma"],"prefix":"10.1111","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8781-3327","authenticated-orcid":false,"given":"Brian T.","family":"Hill","sequence":"first","affiliation":[{"name":"Cleveland Clinic Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta","family":"Nastoupil","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison M.","family":"Winter","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6295-5433","authenticated-orcid":false,"given":"Melody R.","family":"Becnel","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7482-178X","authenticated-orcid":false,"given":"James R.","family":"Cerhan","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5084-0698","authenticated-orcid":false,"given":"Brian K.","family":"Link","sequence":"additional","affiliation":[{"name":"University of Iowa Hospitals and Clinics Iowa City IA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1867-0526","authenticated-orcid":false,"given":"Matthew J.","family":"Maurer","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Fakhri","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine Saint Louis MO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prathima","family":"Reddy","sequence":"additional","affiliation":[{"name":"Seattle Cancer Care Alliance University of Washington Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Smith","sequence":"additional","affiliation":[{"name":"Seattle Cancer Care Alliance University of Washington Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruvika","family":"Mukhija","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Jagadeesh","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Desai","sequence":"additional","affiliation":[{"name":"University of Miami\/Sylvester Comprehensive Cancer Center Miami FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Alderuccio","sequence":"additional","affiliation":[{"name":"University of Miami\/Sylvester Comprehensive Cancer Center Miami FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izidore S.","family":"Lossos","sequence":"additional","affiliation":[{"name":"University of Miami\/Sylvester Comprehensive Cancer Center Miami FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Mehra","sequence":"additional","affiliation":[{"name":"University of Virginia Charlottesville VA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A.","family":"Portell","sequence":"additional","affiliation":[{"name":"University of Virginia Charlottesville VA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max L.","family":"Goldman","sequence":"additional","affiliation":[{"name":"Emory University Atlanta GA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7592-9023","authenticated-orcid":false,"given":"Oscar","family":"Calzada","sequence":"additional","affiliation":[{"name":"Emory University Atlanta GA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon B.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Emory University Atlanta GA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad J.","family":"Hussain","sequence":"additional","affiliation":[{"name":"Levine Cancer Institute Charlotte NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilanjan","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Levine Cancer Institute Charlotte NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Caimi","sequence":"additional","affiliation":[{"name":"University Hospitals of Cleveland Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Tiutan","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College\u2010New York Presbyterian Hospital New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7813-1551","authenticated-orcid":false,"given":"Peter","family":"Martin","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College\u2010New York Presbyterian Hospital New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhigna","family":"Kodali","sequence":"additional","affiliation":[{"name":"Tufts University School of Medicine and Cancer Center Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Evens","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey New Brunswick New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad S.","family":"Kahl","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine Saint Louis MO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,12,21]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_8_4_1","article-title":"Immunochemotherapy with obinutuzumab or rituximab in previously untreated follicular lymphoma (FL) in the randomized phase III gallium study: analysis by chemotherapy regimen","author":"Hiddemann W.","year":"2017","journal-title":"EHA Learning Center"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.1561"},{"key":"e_1_2_8_6_1","first-page":"484","article-title":"Assessment of maintenance rituximab after First\u2010Line Bendamustine\u2010Rituximab in patients with follicular lymphoma: an analysis from the BRIGHT trial","volume":"130","author":"Kahl B.S.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614598"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13895"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.5827"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.613.613"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-481341"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_8_14_1","first-page":"483","article-title":"Four versus two years of rituximab maintenance (r\u2010maintenance) following Bendamustine Plus Rituximab (B\u2010R): initial results of a prospective, randomized multicenter phase 3 study in first\u2010line follicular lymphoma (the StiL NHL7\u20102008 MAINTAIN study)","volume":"130","author":"Rummel M.J.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"e_1_2_8_16_1","first-page":"486","article-title":"Long term follow\u2010up of the PRIMA study: half of patients receiving rituximab maintenance remain progression free at 10\u00a0years","volume":"130","author":"Salles G.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2139"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30097-3"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30618-1"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15720","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15720","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.15720","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15720","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T22:03:24Z","timestamp":1694297004000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,21]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1111\/bjh.15720"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15720","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,21]]},"assertion":[{"value":"2018-08-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}